Pulse Biosciences (NASDAQ:PLSE) Trading Up 5.2% – Time to Buy?

Pulse Biosciences, Inc. (NASDAQ:PLSE)’s share price rose 5.2% on Tuesday . The stock traded as high as $18.52 and last traded at $18.53. Approximately 11,517 shares changed hands during trading, a decline of 90% from the average daily volume of 113,105 shares. The stock had previously closed at $17.61.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of Pulse Biosciences to a “sell” rating in a research report on Thursday, January 2nd.

Pulse Biosciences Stock Down 4.8 %

The business has a fifty day moving average price of $18.29 and a 200-day moving average price of $17.65.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings results on Wednesday, October 30th. The company reported ($0.21) EPS for the quarter. During the same quarter last year, the company posted ($0.19) EPS.

Insider Transactions at Pulse Biosciences

In related news, CEO Burke Thomas Barrett sold 50,000 shares of the company’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total transaction of $871,000.00. Following the completion of the sale, the chief executive officer now directly owns 63,172 shares in the company, valued at $1,100,456.24. This represents a 44.18 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Robert W. Duggan acquired 55,256 shares of the firm’s stock in a transaction on Friday, December 13th. The stock was purchased at an average price of $17.18 per share, for a total transaction of $949,298.08. Following the transaction, the director now directly owns 42,328,717 shares of the company’s stock, valued at approximately $727,207,358.06. This trade represents a 0.13 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 71.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of PLSE. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of Pulse Biosciences during the third quarter valued at approximately $588,000. Charles Schwab Investment Management Inc. increased its position in Pulse Biosciences by 193.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock valued at $2,598,000 after purchasing an additional 97,565 shares during the period. State Street Corp raised its holdings in Pulse Biosciences by 17.8% in the 3rd quarter. State Street Corp now owns 461,333 shares of the company’s stock worth $8,092,000 after purchasing an additional 69,696 shares in the last quarter. Franklin Resources Inc. purchased a new stake in shares of Pulse Biosciences in the 3rd quarter worth about $378,000. Finally, Geode Capital Management LLC boosted its stake in shares of Pulse Biosciences by 7.8% during the 3rd quarter. Geode Capital Management LLC now owns 457,165 shares of the company’s stock valued at $8,020,000 after purchasing an additional 33,200 shares in the last quarter. Institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.